This document summarizes the parameters of a Markov model that compares the costs and life years of monotherapy versus combination therapy for treating a disease. It includes transition probabilities between different health states (A, B, C, D), direct medical costs and community care costs for each state, drug costs, treatment effect, discount rates for costs and benefits, and outputs of the Markov model comparing total life years and costs for each treatment strategy over time. Combination therapy was found to increase life years by 0.95 years but also increased total costs by £5,938 compared to monotherapy, resulting in an incremental cost-effectiveness ratio of £6,276.
This document summarizes the parameters of a Markov model that compares the costs and life years of monotherapy versus combination therapy for treating a disease. It includes transition probabilities between different health states (A, B, C, D), direct medical costs and community care costs for each state, drug costs, treatment effect, discount rates for costs and benefits, and outputs of the Markov model comparing total life years and costs for each treatment strategy over time. Combination therapy was found to increase life years by 0.95 years but also increased total costs by £5,938 compared to monotherapy, resulting in an incremental cost-effectiveness ratio of £6,276.
This document summarizes the parameters of a Markov model that compares the costs and life years of monotherapy versus combination therapy for treating a disease. It includes transition probabilities between different health states (A, B, C, D), direct medical costs and community care costs for each state, drug costs, treatment effect, discount rates for costs and benefits, and outputs of the Markov model comparing total life years and costs for each treatment strategy over time. Combination therapy was found to increase life years by 0.95 years but also increased total costs by £5,938 compared to monotherapy, resulting in an incremental cost-effectiveness ratio of £6,276.
This document summarizes the parameters of a Markov model that compares the costs and life years of monotherapy versus combination therapy for treating a disease. It includes transition probabilities between different health states (A, B, C, D), direct medical costs and community care costs for each state, drug costs, treatment effect, discount rates for costs and benefits, and outputs of the Markov model comparing total life years and costs for each treatment strategy over time. Combination therapy was found to increase life years by 0.95 years but also increased total costs by £5,938 compared to monotherapy, resulting in an incremental cost-effectiveness ratio of £6,276.
Download as XLS, PDF, TXT or read online from Scribd
Download as xls, pdf, or txt
You are on page 1/ 5
Parameters of the model
Name live alpha beta description
Transition probabilities
tpA2A 0.721 1251 483 Transition probability from A to A
tpA2B 0.202 350 1384 Transition probability from A to B tpA2C 0.067 116 1618 Transition probability from A to C tpA2D 0.010 17 1717 Transition probability from A to D tpB2B 0.581 731 527 Transition probability from B to B tpB2C 0.407 512 746 Transition probability from B to C tpB2D 0.012 15 1243 Transition probability from B to D tpC2C 0.750 1312 437 Transition probability from C to C tpC2D 0.250 437 1312 Transition probability from C to D
Costs
dmca £ 1,701 Direct medical costs associated with state A
dmcb £ 1,774 Direct medical costs associated with state B dmcc £ 6,948 Direct medical costs associated with state C ccca £ 1,055 Community care costs associated with state A cccb £ 1,278 Community care costs associated with state B cccc £ 2,059 Community care costs associated with state C
